Quadruple Valve Replacement with Mechanical Valves: An 11-Year Follow-up Study
Background: We performed the first quadruple valve replacement with mechanical valves, combined with the correction of complex congenital heart disease on November 17, 1999. We report here the 11-year follow-up study.
Methods: A 47-year-old man with subacute rheumatic endocarditis, a ventricular septal defect, and an obstruction of the right ventricular outflow tract required replacement of the aortic, mitral, tricuspid, and pulmonary valves; repair of the ventricular septal defect; and relief of the obstruction of the right ventricular outflow tract. The surgery was done on November 17, 1999, after careful systemic preparation of the patient. Warfarin therapy with a target international normalized ratio (INR) range of 1.5 to 2.0 was used. Follow-up included monitoring the INR, recording the incidences of thromboembolic and bleeding events, electrocardiography, radiography, and echocardiography evaluations.
Results: The patient's INR was maintained between 1.5 and 2.0. All 4 mechanical prosthetic heart valves worked well. He is in generally good health without any thromboembolic or bleeding complications.
Conclusions: Long-term management is challenging for patients who have experienced quadruple valve replacement with mechanical valves; however, promising results could mean that replacement of all 4 heart valves in 1 operation is feasible in patients with quadruple valve disease, and an INR of 1.5 to 2.0 could be appropriate for Chinese patients with undergoing valve replacement with mechanical valves.
Alsoufi B, Rao V, Borger MA, et al. 2006. Short- and long-term results of triple valve surgery in the modern era. Ann Thorac Surg 81:2172-7; discussion 2177-8.nBonow RO, Carabello BA, Kanu C, et al. 2006. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114:e84-231.nBrown PS Jr, Roberts CS, McIntosh CL, Swain JA, Clark RE. 1993. Late results after triple-valve replacement with various substitute valves. Ann Thorac Surg 55:502-8.nCannegieter SC, Rosendaal FR, Briet E. 1994. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89:635-41.nChenhsu RY, Chiang SC, Chou MH, Lin MF. 2000. Long-term treatment with warfarin in Chinese population. Ann Pharmacother 34:1395-401.nCortelazzo S, Finazzi G, Viero P, et al. 1993. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 69:316-20.nDong L, Shi YK, Tian ZP, Ma JY, Wang X, Yi J. 2003. Low intensity anticoagulation therapy after mechanical heart valve replacement [in Chinese]. Zhonghua Wai Ke Za Zhi 41:250-2.nEitz T, Schenk S, Fritzsche D, et al. 2008. International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement. Ann Thorac Surg 85:949-54; discussion 955.nGalloway AC, Grossi EA, Baumann FG, et al. 1992. Multiple valve operation for advanced valvular heart disease: results and risk factors in 513 patients. J Am Coll Cardiol 19:725-32.nGohlke-Bärwolf C, Acar J, Oakley C, et al. 1995. Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 16:1320-30.nHossack KF, Hopeman AR, Sutherland EW 3rd. 1987. Long-term follow-up of a patient with quadruple valve replacement. Tex Heart Inst J 14:315-7.nKoertke H, Zittermann A, Tenderich G, et al. 2007. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the Early Self-Management Anticoagulation Trial II. Eur Heart J 28:2479-84.nKudo T, Kawase M, Kawada S, et al. 1999. Anticoagulation after valve replacement: a multicenter retrospective study. Artif Organs 23:199-203.nLevine MN, Raskob G, Hirsh J. 1989. Hemorrhagic complications of long-term anticoagulant therapy. Chest 95:26S-36S.nLevine MN, Raskob G, Landefeld S, Kearon C. 2001. Hemorrhagic complications of anticoagulant treatment. Chest 119:108S-21S.nMori T, Asano M, Ohtake H, et al. 2002. Anticoagulant therapy after prosthetic valve replacement-optimal PT-INR in Japanese patients. Ann Thorac Cardiovasc Surg 8:83-7.nSalem DN, Stein PD, Al-Ahmad A, et al. 2004. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:457S-82S.nSeeburger J, Groesdonk H, Borger MA, et al. 2009. Quadruple valve replacement for acute endocarditis. J Thorac Cardiovasc Surg 137:1564-5.nSun X, Hu S, Qi G, Zhou Y. 2003. Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves. Chin Med J (Engl) 116:1175-8.nUetsuka Y, Hosoda S, Kasanuki H, et al. 2000. Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single institution using conversion from thrombotest to PT-INR. Heart Vessels 15:124-8.nZhou XM, Zhuang W, Hu JG, Li JM, Yu JF, Jiang L. 2005. Low-dose anticoagulation in Chinese patients with mechanical heart valves. Asian Cardiovasc Thorac Ann 13:341-4.nZhuang W, Zhou XM, Hu JG, et al. 2004. Anticoagulation in Chinese patients with Carbomedics mechanical prosthetic heart valves [in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 29:460-2.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).